Figure 1.

Course of Platelet Counts, anticoagulation treatment, and D-Dimers. Recurrent thrombocytopenia (A) and D-Dimer elevations (B) in perspective to disease onset (in days) on the x-axis. The grey area indicates the platelet range for thrombocytopenia. Intravenous immune globuline (IVIG) doses refer to the total doses (~2 g/kg body weight) administered at two or three consecutive days (each arrow indicates an administration). Dosages of anticoagulants were as follows: argatroban: aPTT controlled administration with changing dosage (aiming at aPTT of 60 s; approximately 2 µg/kg/min); tinzaparin: 12.000 U/day s.c.; danaparoid: 750 U s.c. × 3 times/d according to anti-Xa-Level; fondaparinux: 7.5 mg/d s.c.; Fondaparinux was administered until the treatment goal was changed to best supportive care after diagnosis of malignant recurrent ICH.